Drug Trial Radar · NCT07844447
A Study of RT036 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
308
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Oct 30, 2029
Study completion Oct 30, 2029
Sponsor
- Lead sponsor
- Shanghai Ruotuo Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of RT036 in Subjects with Advanced Malignant Solid Tumour. In dose escalation and dose expasion phase, the safety, tolerability of RT036 in patients with advanced malignant solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase 2 dose (RP2D) of RT036. In clinical expansion phase, the preliminary antitumor activity of RT036 in target solid tumors will be evaluated. In addition, the pharmacokinetic characteristics, and immunogenicity of RT036 in patients with advanced malignant solid tumors will be evaluated.
Conditions
- Advanced Malignant Solid Tumours
Interventions
RT036 for injectionDrug
Intravenous (IV) Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTTime frame: Up to 12 months
- MTDTime frame: Up to 12 months
- RP2DTime frame: Up to 12 months
- AETime frame: Up to 36 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.